STOCK TITAN

BioAtla (BCAB) S-3 Filings

BCAB OTC

Here are the S-3 shelf registrations from BioAtla Inc (BCAB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.

Rhea-AI Summary

BioAtla, Inc. has filed a new shelf registration statement on Form S-3 allowing it to offer and sell up to $200,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The filing carries forward $195.95 million of unsold securities from a prior shelf under Rule 415(a)(6). A related prospectus supplement covers up to $18.75 million of common stock that may be issued to YA II PN, Ltd., Anson Investments Master Fund LP and Anson East Master Fund LP under Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement, and also permits those investors to resell such shares. As of mid-January 2026, BioAtla’s public float was about $74.4 million, so sales under this shelf are limited by the one‑third cap in General Instruction I.B.6 of Form S‑3. The company’s stock trades on Nasdaq under the symbol “BCAB.”